148 148
Conflicts of interest:
All authors declare no con
fl
icts of interest.
References
[1]
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737 – 46.
[2]
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to fi rst-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163 – 77.
[3]
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149 – 58.
[4]
Fizazi K, Tran N,[9_TD$DIFF]
Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;[10_TD$DIFF]
377:352 – 60.
[5]
James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338 – 51.
a
Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST,
Genoa, Italy
b
Department of Internal Medicine, School of Medicine, University of Genoa,
Genoa, Italy
c
Oncology Unit, Istituto Fondazione G. Giglio, Cefalu
’
, Italy
*Corresponding author. Academic Unit of Medical Oncology, Policlinico
Hospital San Martino-IST, Largo R. Benzi 10, 16132 Genoa, Italy;
Department of Internal Medicine, School of Medicine, University of
Genoa, Genoa, Italy. Fax: +39 010352753.
E-mail address:
carlo.messi@hotmail.it(C. Messina
a
[5_TD$DIFF]
).
July 25, 2017
http://dx.doi.org/10.1016/j.eururo.2017.07.030E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 14 5
–
14 8
148